Biosimilars: Extrapolation for oncology
Keywords
Cited by (0)
Giuseppe Curigliano, MD, PhD, is Director at the IEO, Division of Experimental Therapeutics. He is a clinician and researcher specializing in breast cancer and new drug development. Dr Curigliano is associate editor for The Breast, and a member of the editorial board of Journal of Clinical Oncology, Annals of Oncology and Cancer Treatment Reviews. Dr Curigliano has published many papers and reviews for a number of prestigious oncology journals.
Darran P. O’Connor, PhD, is Senior Lecturer in Clinical Pharmacology in the Department of Molecular & Cellular Therapeutics at the Royal College of Surgeons in Ireland. He is a cancer biologist focused on the discovery, validation and clinical translation of novel cancer biomarkers.
Julie Ann Rosenberg, MD, is a Senior Director Asset Lead, Biosimilars, Pfizer Worldwide Research and Development, United States.
Ira A. Jacobs, MD, MBA, FACS, is a fellowship trained surgical oncologist who is the oncology biosimilars global medical lead at Pfizer, Inc.